CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.39B, above the global median of $1.18B
- FinancialsAltman Z-Score 7.21: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.39BUSDvs all stocks (USD)
Revenue (TTM)
36.77MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.80xvs all stocks
52-Week Change
147.95%vs all stocks
Market Capitalization
2.39BUSDvs all stocks (USD)
Enterprise Value
2.00BUSDvs all stocks (USD)
Forward P/E
-21.60xvs Biotechnology peers
Price to Sales (TTM)
64.95xvs Biotechnology peers
Price to Book (MRQ)
5.93xvs Biotechnology peers
Enterprise to Revenue
54.47xvs Biotechnology peers
Enterprise to EBITDA
-5.67xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1041.73%vs Biotechnology peers
Return on Assets (TTM)
-40.06%vs Biotechnology peers
Return on Equity (TTM)
-80.30%vs Biotechnology peers
Revenue (TTM)
36.77MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.3670USDUpdated Sep 28, 2026Quarterly Revenue Growth
-79.50%vs Biotechnology peers
Gross Profit (TTM)
-304.17MUSDvs all stocks (USD)
EBITDA (TTM)
-353.18MUSDvs all stocks (USD)
Net Income (TTM)
-341.35MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-79.47%vs Biotechnology peers
Operating Cash Flow (TTM)
-293.70MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-164.64MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
83.98MUSDFY2025 · Nov 30, 2025Operating Income
-285.67MUSDvs all stocks (USD)
Pre-tax Income
-263.70MUSDFY2025 · Nov 30, 2025Income Tax Expense
760.00KUSDFY2025 · Nov 30, 2025Net Income
-264.46MUSDFY2025 · Nov 30, 2025EBIT
-285.67MUSDFY2025 · Nov 30, 2025EBITDA (Income Statement)
-266.81MUSDFY2025 · Nov 30, 2025Research & Development
316.90MUSDFY2025 · Nov 30, 2025Selling, General & Administrative
52.74MUSDFY2025 · Nov 30, 2025Non-operating Interest Income
21.97MUSDFY2025 · Nov 30, 2025Net Income from Continuing Operations
-264.46MUSDFY2025 · Nov 30, 2025Operating Cash Flow
-250.31MUSDFY2025 · Nov 30, 2025Free Cash Flow
-264.31MUSDFY2025 · Nov 30, 2025Cash & Cash Equivalents (End of Period)
247.93MUSDFY2025 · Nov 30, 2025Starting Profit (CF Statement)
-264.46MUSDFY2025 · Nov 30, 2025Depreciation & Amortization
18.86MUSDFY2025 · Nov 30, 2025Stock-based Compensation
37.97MUSDFY2025 · Nov 30, 2025Change in Accounts Payable (CF)
-630.00KUSDFY2025 · Nov 30, 2025Change in Other Assets/Liabilities
-42.05MUSDFY2025 · Nov 30, 2025Capital Expenditures
-14.00MUSDFY2025 · Nov 30, 2025Purchase of Investments
-455.69MUSDFY2025 · Nov 30, 2025Sale of Investments
617.54MUSDFY2025 · Nov 30, 2025Net Investing Cash Flow
147.85MUSDFY2025 · Nov 30, 2025Net Financing Cash Flow
234.76MUSDFY2025 · Nov 30, 2025Shares Outstanding
103.70MSharesUpdated Sep 28, 2026Float Shares
74.11MSharesUpdated Sep 28, 2026Shares Short
17.98MSharesUpdated Sep 28, 2026Short Ratio
14.59daysvs all stocks
Short % of Shares Outstanding
17.52%vs all stocks
% Held by Insiders
1.08%vs all stocks
% Held by Institutions
114.83%vs all stocks
Total Cash (MRQ)
443.53MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.27USDUpdated Sep 28, 2026Total Debt (MRQ)
58.14MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1444xvs Biotechnology peers
Current Ratio (MRQ)
6.34xvs Biotechnology peers
Book Value per Share (MRQ)
3.88USDUpdated Sep 28, 2026Total Assets
688.13MUSDvs all stocks (USD)
Total Current Assets
606.82MUSDFY2025 · Nov 30, 2025Total Liabilities
149.39MUSDFY2025 · Nov 30, 2025Total Non-current Assets
81.32MUSDFY2025 · Nov 30, 2025Total Non-current Liabilities
62.92MUSDFY2025 · Nov 30, 2025Total Current Liabilities
86.47MUSDFY2025 · Nov 30, 2025Cash & Cash Equivalents
246.96MUSDFY2025 · Nov 30, 2025Other Short-term Investments
345.98MUSDFY2025 · Nov 30, 2025Accounts Payable
11.21MUSDFY2025 · Nov 30, 2025Short-term Debt
2.82MUSDFY2025 · Nov 30, 2025Deferred Revenue
17.58MUSDFY2025 · Nov 30, 2025Other Current Liabilities
2.10MUSDFY2025 · Nov 30, 2025Long-term Debt
52.91MUSDFY2025 · Nov 30, 2025Common Stock (Book)
102.00KUSDFY2025 · Nov 30, 2025Retained Earnings
-1.00BUSDFY2025 · Nov 30, 2025Total Shareholders' Equity
538.75MUSDvs all stocks (USD)
52-Week Low
8.85USDUpdated Sep 28, 202652-Week High
28.23USDUpdated Sep 28, 202652-Week Change
147.95%vs all stocks
Beta
1.80xvs all stocks
50-Day MA
25.27USDUpdated Sep 28, 2026200-Day MA
19.48USDUpdated Sep 28, 2026Avg 10-Day Volume
1.61MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.34MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-3.46USDUpdated Sep 28, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 7.21: safe zoneNotable
Altman Z-Score: 7.21
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.39B, above the global median of $1.18BNotable
Market cap (USD): 2,388,016,525Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
BrightGene Bio-Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Harmony Biosciences Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Immunome Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sellas Life Sciences Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Vera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Celldex Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Viridian Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Dongbao Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Double Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Buchang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule